{"id":"W2604445332","doi":"10.1200/jco.2013.31.15_suppl.tps4157","title":"INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced esophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; Saint John Regional Hospital","funders":"","keywords":"Medicine; Regorafenib; Clinical endpoint; Internal medicine; Bevacizumab; Placebo; Oncology; Phases of clinical research; Surrogate endpoint; Adverse effect; Ramucirumab; Cancer; Progression-free survival; Clinical trial; Surgery; Chemotherapy; Colorectal cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002135481,0.002953455,0.003799215,0.0006986537,0.000538501,0.001319245,0.001233521,0.002282737,0.01459331],"category_scores_gemma":[0.001947996,0.0009100574,0.002381898,0.0006205541,0.001506599,0.001466081,0.0005584667,0.00375404,0.002347415],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006919634,"about_ca_system_score_gemma":0.001547057,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007706331,"about_ca_topic_score_gemma":0.002025326,"domain_scores_codex":[0.9993513,0.0003328252,0.00004472286,0.0001097751,0.00006376747,0.00009769267],"domain_scores_gemma":[0.9991536,0.0001406746,0.0002265058,0.00009077394,0.00007110889,0.0003173238],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9815211,0.005337269,0.0003220211,0.0006750972,0.000683653,0.00002990941,0.00003277059,0.000141584,0.001866296,0.00008895575,0.0008857009,0.008415682],"study_design_scores_gemma":[0.9777789,0.0210081,0.0003701712,0.00001454596,0.0001691551,0.00001203103,0.000008525178,0.00005428287,0.0001053348,0.0000472767,0.0004266984,0.000004899386],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9483083,0.0107678,0.001505313,0.002085202,0.001856932,0.02353164,0.005150732,0.0006234495,0.006170715],"genre_scores_gemma":[0.9356515,0.007803485,0.003699142,0.003654315,0.001482724,0.03152987,0.005207386,0.00009590307,0.01087563],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01459331,"threshold_uncertainty_score":0.04881948,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1461416750695312,"score_gpt":0.4933522990577978,"score_spread":0.3472106239882666,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}